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Dr. King has
invited Dr. Lloyd
Klein to share his
thoughts in this
space.The university chemistry professor and his hospital administrator wife sat in my ofﬁce, staring in
astonishment. My medical evaluation was divergent from 2 other consultants who had given
conﬂicting opinions. I was supposed to “break the tie,” but instead, I had outlined a third treatment
strategy. These two highly analytical people wanted to know: how could three cardiologists come
to such diverse answers based on the same medical information? Wasn’t there something like
a decision tree, in which there was a logical sequence to follow based on the results of tests and the
severity of disease?
How doctors determine which treatment choice to employ is almost never formally discussed.
Cardiology societies have created detailed guideline documents and appropriate use criteria,
counseling that clinical decisions be supported by the evidence base, which is gathered and
developed from clinical trial results and registry data. However, as this case of stable angina
illustrates, there is wide variability in how physicians evaluate symptom severity and interpret test
results. There are frequently differences of opinion as to whether a patient ﬁts into a particular trial
or may have been excluded on the basis of the study’s inclusion criteria. Consequently, the
application of existing knowledge to patient management is often ambiguous.
Increasingly, this is not merely an “ivory tower” dilemma; how clinical decisions are made
transcends our view of who is a good doctor and whether a patient is being managed appropriately
and cost effectively. As physician report cards and reimbursement based on outcomes enter
everyday practice, misunderstandings between those who make the decisions and those who
appraise them may create a “Tower of Babel” predicament in which lack of communication leads to
incorrect physician quality assessments. We have all observed cases in which an accomplished
physician made a decision with which we disagreed; sometimes, discussing the circumstances with
that doctor illuminates unrecognized details or considerations. As cardiology proceeds with
external evaluations of quality, it is important that doctors comprehend how we think so we can
explain the process to those who do not routinely make medical decisions.How do doctors think? Although cardiologists take great pride in our scientiﬁc and quantitative
backgrounds, and genuinely believe that the science of medicine is central to making logical
decisions, in fact, medical decision making is more art than science. Most of us have a poor
comprehension of the interplay between these 2 aspects of our skill set.
The classic manner in which physicians are taught to make a provisional diagnosis is symptom
based: we evaluate each patient complaint and arrive at a list of possible explanations, the “differential
diagnosis.” Rather than following a formal logic system, physicians think empirically, and solve
problems heuristically; that is, the diagnosis is arrived at through an experimental mental process of
trial and error. Doctors initially conjecture which possibilities are most common or most critical to
exclude ﬁrst, then discard those and try out others when evidence arises that makes them less likely
(1). Sometimes, intuition is relied upon, and ﬁrst impressions are often correct. When to consider an
unlikely, but grave, diagnosis as opposed to a common and more likely but less serious one may be
triggered by a patient’s choice of phrase or a laboratory test result. Doctors also think systemically,
that is, we evaluate symptoms in the context of diseases or risk factors the patient is known to have.
There is no established organized structure to diagnostic problem solving. Although algorithms
have been developed for several situations, the foundation of these methods remains rooted in the
symptom-based methods of the past, which are inherently less useful when symptoms are vague or
test results have multiple possible explanations.
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990Therapeutic decision making. Therapeutic decisions are
based on randomized trial results ﬁltered through
personal observations of howprevious patients fared.Not
infrequently, doctors reach similar conclusions but arrive
there by different reasoning. The reason is that in coro-
nary heart disease, there are just 3 strategic choic-
esdbypass surgery, stenting, and medical therapydand
all are effective to some extent in everybody. Preference
among them arises because there are intrinsic drawbacks
to each and because the likelihood of risk varies
depending on individual circumstances. The challenge is
to determine whether 1 modality holds a special advan-
tage or disadvantage for the individual patient. No
patient wants to endure the pain and recuperative process
of surgery if there is no incremental beneﬁt; conversely,
no patient will accept the cost and hassle of multiple
medications and their adverse effects if there is a better
alternative. Further, it is reasonable to avoid expensive
procedures unless there is somemeasurable improvement
over other options. There is no objective way to compare
different rates of successes and failures on a subjective,
and individual, scale as to which to anticipate and which
to fear among the outcomes.
One major gap in our understanding is appreciating
how evidence from clinical trials are incorporateddor
notdinto everyday practice. For example, evaluations
of the impact of the COURAGE (Clinical Outcomes
Utilizing Revascularization and Aggressive Drug
Evaluation) trial and OAT (Occluded Artery Trial)
have shown that these trials and ensuing guidelines
have resulted in little or no change in practice. This
result has been misunderstood as interventional
cardiologists’ lacking interest in scientiﬁc evidence, or
worse, a preoccupation with income. The reality is that
these studies’ designs resulted in a large number of
exceptions. Additionally, the development of drug-
eluting stents while these studies were in progress has
raised questions if the results are applicable in
contemporary practice.
Assessing quality: getting with the guidelines. To know
what quality practice entails requires the collection of
standardized data that accurately reﬂect patient risk,
treatment, and outcome. Monitoring how guideline-
mandated therapies are used after implementing
quality improvement efforts and then measuring how
these changes impact outcomes is the process used to
improve practice. Yet certain drug treatments and
interventions (2,3) are not always used as mandated by
guidelines. Interventional cardiologists should be able
to justify when clinical decisions are made that are not
fully aligned with guidelines; however, their uncritical
application without regard for their limitations may
also lead to deﬁcient outcomes. A basic question that
must be asked is why interventionists do not followsome guidelines if they are indeed the cornerstone of
quality.
One highly cited example is the Appropriate Use
Criteria for Coronary Revascularization (3), an algo-
rithm developed from a matrix of clinical variables
describing when bypass surgery, coronary stenting, or
medical therapy is best employed, keyed to the medical
evidence. This tool serves as a quality metric in
combination with the National Cardiovascular Data
Registry (4). Although a very useful starting point,
especially to evaluate populations of patients, this tool
is imperfect when applied to individuals (5). The
appropriate use criteria assume the absence of exten-
uating circumstances and that the patient has no
strong feelings as to what treatment strategy should be
employed (6). Because every patient is unique, and
nearly all have preconceived notions concerning
treatment choices, these assumptions oversimplify
decision making. Although usually applicable in clin-
ical practice, there must be some leeway for speciﬁc
cases with unusual attributes or concerns.
Another problem is that there are differing opinions
as to what constitutes a clinically meaningful effect.
Obviously, mortality is 1 crucial outcome measure to
determine efﬁcacy, but it is not the only relevant
endpoint; stroke and myocardial infarction are also
important endpoints. How should a cardiologist
interpret SYNTAX, which showed beneﬁt for some
endpoints for surgery and beneﬁt for stenting with
other endpoints? The need for additional procedures,
repeat hospitalization, sustained angina relief, less
medication use, and quality of life are also important.
These “soft” endpoints are not the primary outcomes
of most clinical trials, but to patients, these may be
more vital in making decisions than clinical outcomes.
When confronted with an elderly patient who is most
concerned with improving quality of life, cardiologists
have almost no hard data for reference (7).
Another major inﬂuence is that of risk aversion. Risk
aversion is a reaction to uncertainty in decision making.
Although most humans seek the choice that minimizes
uncertainty and risk, rational decisions take into account
the potential beneﬁts, and the opportunity cost of losing
the potential advantages, of riskier choices. Most physi-
cians and patients tend to choose the course they consider
to have the lowest risk, rather than the one that optimizes
overall beneﬁt. Additionally, it is my observation that it is
a perception of higher short-term risk, even if the long-
term risk is similar or actually lower, that leads to risk-
averse medical decision making. In part, this behavior is
strongly inﬂuenced by the medical malpractice system, in
which a bad short-term result is a basis for legal action.
Further, it is emotionally powerful for the physician to
select a treatment strategy only to witness a complication
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991consequent to that choice. The advent of national regis-
tries and states with public reporting accentuate this
apprehension by measuring only the short-term down-
side. The same quality assurance methods that physicians
implement for self-assessment rewards risk aversion by
equating complications with lack of skill, which is often
inaccurate.
Implications for quality assurance. All of these
factors played a role in my assessment of the university
professor. He chose the medication route I advised.
He lost weight, found time to exercise several times
a week despite continuing to teach and do research,
and changed his diet. He remained asymptomatic for
over 10 years, never requiring any further procedures.
But that is not the end of the story. Although this
patient vignette has a happy ending, was it the only
solution that should be made available? Just because 1
patient does well does not indicate that the decision
making was ﬂawless. Do the other 2 cardiologists
deserve criticism for an incorrect therapeutic plan? If
angina had worsened in year 2 or 3, necessitating an
emergent procedure, would that have rendered my
advice incorrect? The choice of which therapeutic
alternative is best should ideally be the patient’s
decision; our role as physicians is to teach and advise.
In a brave new world of electronic medical records,
and administrative and professional databases, it is
critical to facilitate clear communication among the
various stakeholders and assure the accurate inter-
change of data and information. It is of no beneﬁt to
anyone if the physicians managing the patient and the
administrative personnel assessing a system-wide
approach are not communicating. Not understanding
how interventional cardiologists think raises problems
that will be confronted when physician reimbursement
is increasingly made on the basis of results, not fee-
for-service. If the healthcare system fails to develop
a mechanism for decision review that considers how
doctors make decisions, it will predictably and inevi-
tably lead to disillusionment. Which “results” are
important to society? How much differential in cost is
worth what degree of improved outcomes and what
level of patient and physician comfort with the deci-
sions? Will the wealthy be able to purchase a different
treatment modality that the poor cannot afford?
The serious implication of our confusion as to how
doctors make therapeutic decisions is that there aresome with other agendas who will seek to make them
for us. If we are unable to explain our decision-making
process to patients and third party payers, they may
ﬁnd attractive a formulaic answer that seems to remove
the elements of ambiguity and doubt. When physician
report cards, third-party assessments of hospital and
physician quality, ties between outcomes and reim-
bursement, and the public reporting of outcomes
become realities, who will deﬁne what is quality
practice? And on what basis (8)? It is obligatory that
cardiologists lead the process of developing the most
rigorous and accurate means to measure quality,
develop tools for quality assurance, and support
improvement initiatives through standardized assess-
ment of risk, risk adjustment, clinical process, and
outcome.Reprint requests and correspondence:
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